	US 12,391,993 B2
	Methods, treatment, and compositions for characterizing thyroid nodule
Maria A. Hahn, Duarte, CA (US); John H. Yim, San Marino, CA (US); Yuman Fong, Duarte, CA (US); Arthur X. Li, Covina, CA (US); and Xiwei Wu, Diamond Bar, CA (US)
Assigned to CITY OF HOPE, Duarte, CA (US)
Filed by City of Hope, Duarte, CA (US)
Filed on Jul. 20, 2022, as Appl. No. 17/813,904.
Application 17/813,904 is a continuation of application No. 15/217,645, filed on Jul. 22, 2016, granted, now 11,505,829.
Claims priority of provisional application 62/196,678, filed on Jul. 24, 2015.
Prior Publication US 2023/0227913 A1, Jul. 20, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6886 (2018.01)

CPC C12Q 1/6886 (2013.01) [C12Q 2600/118 (2013.01); C12Q 2600/154 (2013.01)]

20 Claims

1. A method of treating papillary thyroid cancer in a subject in need thereof, the method comprising:

(i) measuring decreased DNA methylation levels, relative to a control, at papillary thyroid carcinoma DNA methylation sites in an isolated DNA obtained from a thyroid nodule from the subject, wherein the papillary thyroid carcinoma DNA methylation sites, with respect to reference human genome assembly hg19, comprise:

(a) chromosome 10, position 112259015,

(b) chromosome 12, position 56115043, and

(ii) administering cabozantinib-S-malate, doxorubicin hydrochloride, lenvatinib mesylate, sorafenib tosylate, vandetanib, or a combination of two or more thereof to the subject having the decreased DNA methylation levels at the papillary thyroid carcinoma DNA methylation sites in step (i) to treat the papillary thyroid cancer.